A Phase 3 interventional study of HX575 epoetin alfa (Sandoz) in Chronic Kidney Disease, sponsored by Sandoz. Completed at 50 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-19.
Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic — 1 open to participants now, 1 under way, none of them phase 3. Epoetin Alfa · Renal Insufficiency, Chronic.
Among the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic, this one is the 7th largest by enrollment, is one of 5 that started in 2012, is one of 10 in phase 3, and was the 18th registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →1 of the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic is open now, in 1 country. Recruiting first, the newest first:
Services Hospital, Lahore · Sites in Pakistan
Ages 18–65
By country, each count listing its studies:
Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2012.
This study's enrollment of 417 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 157 across the 25 interventional studies. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 25 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sandoz, one of the names counted as Novartis. Under that name alone:
Sandoz is the lead sponsor of 139 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
28 studies in Renal Insufficiency, Chronic by Novartis: 4 open now, 6 under way, 5 of them phase 3. Of 20 finished, 11 (55%) have results posted.
Among the 28 studies in Renal Insufficiency, Chronic by Novartis, this one is the 5th largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2012, is one of 12 in phase 3, and was the 13th registered.
Novartis’s Renal Insufficiency, Chronic studies by the year they started, since 2004.
1 of the studies testing Epoetin Alfa in Renal Insufficiency, Chronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07755683Services Hospital, LahoreEffect of Daprodustat and Epoetin Alpha on Anemia in Patients Not Undergoing Dialysis | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 28 in Renal Insufficiency, Chronic:
This tab as a report to print or save as PDF → With an account.
The study will assess the immunogenicity, safety, and efficacy of HX575 epoetin alfa administered subcutaneously (s.c.) in patients suffering from anemia due to chronic kidney disease (CKD)
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single arm
Drug: HX575 epoetin alfa (Sandoz)
Eligible patients are scheduled to receive HX575 (INN: Epoetin alfa) as a solution for injection in order to achieve or maintain the correction of renal anemia.
Also known as: Binocrit®, Epoetin alfa HEXAL®, Novicrit®, Abseamed®
Anti-Erythropoietin (EPO) Antibodies
The incidence of antibody formation against epoetin in Radio-immuno-precipitation (RIP) assay
Time frame: 52 weeks
Hemoglobin Level and Change From Baseline Period at Visit 16 (End of Study)
Actual values of hemoglobin levels at end of study visit and change from Baseline Period (Week -4 to Week -1)
Time frame: 52 weeks
Patients, suffering from anemia associated with chronic Kidney Disease (CKD), were treated s.c. with HX575 at least once per week in order to achieve and maintain Hb concentration within the target range of 10.0 to 12.0 g/dL. 417 patients were enrolled.
| Milestone | HX575, Safety Population |
|---|---|
| Started | 417 |
| Completed | 324 |
| Not completed | 93 |
| Withdrew: Withdrawal by subject | 24 |
| Withdrew: Adverse event | 10 |
| Withdrew: Death | 21 |
| Withdrew: Physician decision | 2 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Kidney transplantation | 10 |
| Withdrew: Protocol violation | 12 |
| Withdrew: Other | 12 |
The incidence of antibody formation against epoetin in Radio-immuno-precipitation (RIP) assay
| percentage of participants | HX575 |
|---|---|
| Anti-Erythropoietin (EPO) Antibodies | 1.7 (0.7 to 3.4) |
Actual values of hemoglobin levels at end of study visit and change from Baseline Period (Week -4 to Week -1)
| g/dL | HX575 - ESA Naive | HX575 - ESA Maintenance | HX575 |
|---|---|---|---|
| Actual Value | 10.81 ± 1.336 | 10.86 ± 1.060 | 10.83 ± 1.226 |
| Change from Baseline Period | 1.61 ± 1.601 | 0.22 ± 1.223 | 1.02 ± 1.606 |
Collected over 4 weeks (screening period) + 52 weeks (treatment period). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HX575, Safety Population | 25/416 (6%) | 103/416 (24.8%) | 121/416 (29.1%) |
| Event | HX575, Safety Population |
|---|---|
| Renal failure chronicRenal and urinary disorders | 20/416 |
| Myocardial infarctionCardiac disorders | 5/416 |
| PeritonitisInfections and infestations | 5/416 |
| PneumoniaInfections and infestations | 5/416 |
| HypertensionVascular disorders | 5/416 |
| Angina pectorisCardiac disorders | 3/416 |
| Cerebrovascular accidentNervous system disorders | 3/416 |
| Acute coronary syndromeCardiac disorders | 2/416 |
| Acute myocardial infarctionCardiac disorders | 2/416 |
| Angina unstableCardiac disorders | 2/416 |
| Event | HX575, Safety Population |
|---|---|
| HypertensionVascular disorders | 42/416 |
| Renal failure chronicRenal and urinary disorders | 39/416 |
| HyperkalaemiaMetabolism and nutrition disorders | 19/416 |
| NasopharyngitisInfections and infestations | 13/416 |
| PneumoniaInfections and infestations | 10/416 |
| DiarrhoeaGastrointestinal disorders | 9/416 |
| Oedema peripheralGeneral disorders | 9/416 |
| Urinary tract infectionInfections and infestations | 9/416 |
Safety population: The safety population consists of all patients that received at least one dose of study drug
| Age, Continuous(years) | HX575, Safety Population |
|---|---|
| Mean | 52.3 ± 15.78 |
| Sex: Female, Male(Participants) | HX575, Safety Population |
|---|---|
| Female | 218 |
| Male | 198 |
| Race (NIH/OMB)(Participants) | HX575, Safety Population |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 416 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | HX575, Safety Population |
|---|---|
| Russian Federation | 107 |
| Romania | 40 |
| Turkey | 33 |
| Ukraine | 179 |
| Poland | 47 |
| Italy | 5 |
| Germany | 5 |
| Height(cm) | HX575, Safety Population |
|---|---|
| Mean | 166.9 ± 9.44 |
| Weight(kg) | HX575, Safety Population |
|---|---|
| Mean | 70.6 ± 15.92 |
| Body Mass Index (BMI)(kg/m^2) | HX575, Safety Population |
|---|---|
| Mean | 25.26 ± 5.073 |
| ESA pre-treatment(participants) | HX575, Safety Population |
|---|---|
| ESA naive | 250 |
| ESA maintenance | 166 |
The record gives a start of Apr 2012, a primary completion of Oct 2014 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2017, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epoetin Alfa
Renal Insufficiency, Chronic →